CSBio CSBio

X
[{"orgOrder":0,"company":"Biophytis","sponsor":"H.C. Wainwright & Co., LLC","pharmaFlowCategory":"D","amount":"$6.8 million","upfrontCash":"Undisclosed","newsHeadline":"Biophytis Announces a \u20ac 6.1 Million Capital Increase Through Private Placement","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Biophytis"},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Organises a Webcast with Key Opinion Leaders (KOL) On the Phase 2-3 Cova Study Results of Sarconeos (Bio101) In the Treatment of Pneumonia in Covid-19 Patients at Risk of Respiratory Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Biophytis"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            BIO101 (sarconeos), an orally administered small molecule, stimulates biological resilience through activation of the MAS receptor, a key component of the RAS. The RAS is a fundamental endocrine system that control fluid balance, blood pressure and cardio-vascular function.

            Lead Product(s): 20-Hydroxyecdysone

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO101

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Net proceeds of the private placement will be used primarily to progress Biophytis drug development programs, including the COVA clinical study, To begin Sarconeos (BIO101) Phase 2/3 clinical trial as a potential treatment for respiratory failure associated with COVID-19.

            Lead Product(s): 20-Hydroxyecdysone

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO101

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: H.C. Wainwright & Co., LLC

            Deal Size: $6.8 million Upfront Cash: Undisclosed

            Deal Type: Private Placement July 03, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY